Published in

The Royal Society, Biology Letters, 10(12), p. 20160553, 2016

DOI: 10.1098/rsbl.2016.0553

Links

Tools

Export citation

Search in Google Scholar

Demonstration of immune responses against devil facial tumour disease in wild Tasmanian devils

Journal article published in 2016 by Ruth Pye ORCID, Rodrigo Hamede ORCID, Hv Siddle, Alison Caldwell, Gw Knowles, Kate Swift, Alexandre Kreiss, Me Jones ORCID, A. Bruce Lyons, Gm Woods ORCID
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Devil facial tumour disease (DFTD) is a recently emerged fatal transmissible cancer decimating the wild population of Tasmanian devils ( Sarcophilus harrisii ). Biting transmits the cancer cells and the tumour develops in the new host as an allograft. The literature reports that immune escape mechanisms employed by DFTD inevitably result in host death. Here we present the first evidence that DFTD regression can occur and that wild devils can mount an immune response against the disease. Of the 52 devils tested, six had serum antibodies against DFTD cells and, in one case, prominent T lymphocyte infiltration in its tumour. Notably, four of the six devils with serum antibody had histories of DFTD regression. The novel demonstration of an immune response against DFTD in wild Tasmanian devils suggests that a proportion of wild devils can produce a protective immune response against naturally acquired DFTD. This has implications for tumour–host coevolution and vaccine development.